Blogroll
- Ben’s Stem Cell News
- Biosingularity
- Biotech Blog
- Cell WISE
- CellTherapyBlog
- CellTherapyNews
- Fierce Biotech
- Fredrick County, MD Biotech Community
- Hematopoiesis
- IN VIVO blog
- Life Sciences Chronicle
- List of Biotech Conferences
- My Biotech Life
- Partial Immortalization
- Stem Cell Patents
- The Niche
- The Stem Cell
- US PTO
- Venture Beat – Lifesciences
- Wired Blogs – Science
- WordPress.com
Cool Regenmed Jobs
- Biomaterials and Diabetes Scientists at Living Cell Technologies (New Zealand)
- Cell and Tissue Culture Technicians at Pharmacell (ex-US)
- Cell Culture, Bioprocess, Analytical, and Tissue Engineering positions open at Tengion
- Cell Process Development and Production Positions at Cognate Bioservices
- Cell Therapy Business Development Leader at Invitrogen
- Jobs at Geron: chemists, process and product development, cell biology, immunology, assay development, and quality positions
- Manufacturing Manager at Cognate Bioservices
- Process Dev, R&D, Quality and other jobs at Tigenix (Belgium and US)
- RegenMed Scientists and Research Associates at Athersys
- Research and Quality positions at Biomimetic Therapeutics
General Science
Local Biotech Gateways
Other Biotech Blogs
Patents
Archives
Catagory Cloud
adult stem cell Advanced Cell Technology Apptec Athersys BD Big Pharma Biomaterials Bioprocessing business models cardiac regeneration cell delivery Clinical Trials combination products Company Profiles Embyonic Stem Cells FDA Geron Innovation Intellectual Property Invitrogen JNJ Job search Joint Ventures Manufacturing Novocell Osiris Regenerative Medicine regulatory stem cells vascular regeneration
Category Archives: Embyonic Stem Cells
The Developing Embyronic Stem Cell Clinical Landscape
ES cell biopsy from blastocyst. Continue reading
Posted in adult stem cell, Advanced Cell Technology, Athersys, Clinical Trials, Cytori, Embyonic Stem Cells, FDA, Geron, JNJ, Novocell, Osiris, Regenerative Medicine, spinal cord injury, stem cells
Tagged Clinical Trials, embryonic vs adult stem cell, embyryonic stem cell 2008, evolving clinical landscape, safety issues
Leave a comment
Geron Bolsters Extensive Embryonic Stem Cell Patent Estate
Geron yesterday announced the issuance of US patent #7,326,572, helping to extend their patent protection around their embryonic stem (ES) cell platform technology in the area of treating type 1 diabetes. Currently, Geron owns an exclusive license from the Wisconsin … Continue reading
FDA Proactively Addresses Embryonic Stem Cell Safety Testing
The FDA has scheduled an April 10, 2008 meeting to “discuss scientific considerations for safety testing for cellular therapy products derived from human embryonic stem cells.” This meeting will be followed by another meeting on April 11 that will “discuss … Continue reading
Geron publishes data suggesting that Embyonic Stem Cells may not need long term immunosuppression
An interesting study was published this week in the Journal of Neuroimmunology spurring a press release from Geron that stated “GERON’S HUMAN EMBRYONIC STEM (ES) CELL-BASED THERAPEUTIC FOR SPINAL CORD INJURY EVADES DIRECT ATTACK BY THE HUMAN IMMUNE SYSTEM”. The … Continue reading
The Regeneration Station 